Lumida
/RIGL
⌘K
Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals Inc

RIGL
$40.54USD↓-2.71%-1.13 today

MARKET CAP

750.1M

P/E (TTM)

6.4x

FWD P/E

10.4x

DAY RANGE

$40 – $42

52W RANGE

$19
$52

AI Summary

Stalk
StalkMedium

Despite the medium- and long-term bullish structure under a Stage 2 advance, extreme overbought conditions and an active Bullish Exhaustion pattern signal waning upside follow-through; deferred execution is advised, waiting for a pullback into the rising EMA support zone.

  • ↑Q1 sales $54.9M, +26% YoY, driven by Tavalisse growth
  • ↑Maintains 2026 revenue guidance of $275–290M with sequential lift
  • ↓High stock volatility and leverage raise financial stability concerns
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) is a biotechnology company engaged in the development of innovative therapies primarily targeting hematological disorders and oncology. The company has transitioned from a single-product focus to a multi-product offering, with a strong emphasis on addressing unmet medical needs in its targeted sectors. Rigel is strategically positioned within the competitive biotechnology landscape, focused on leveraging its robust pipeline and ongoing product commercialization efforts to enhance revenue streams and market presence.

Bull says

  • ↑Q1 sales $54.9M, +26% YoY, driven by Tavalisse growth
  • ↑Maintains 2026 revenue guidance of $275–290M with sequential lift
  • ↑R289 MDS asset in Phase 1b, FDA fast-track and orphan designations
  • ↑Net income $8.7M in Q1 despite rising R&D expenses
  • ↑$146.7M cash reserves support late-stage trials and operations
  • ↑High profitability and momentum factors with strong institutional interest

Bear says

  • ↓High stock volatility and leverage raise financial stability concerns
  • ↓Analyst revisions trending negative, signaling waning earnings confidence
  • ↓Revenue heavily reliant on Tavalisse amid mounting competition
  • ↓Low ResLydia adoption by community clinicians may dampen sales
  • ↓Eli Lilly partnership termination cuts potential revenue synergies
  • ↓Weak size and dividend yield factors highlight market positioning risk

Investment themes with RIGL

Biotech↓ -3.20%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-09-2026bullish

Transcript signals

Bull points

  • Rigel is a hematology oncology-focused company. We have a growing commercial business. We are profitable, and we have a pipeline in hematology oncology with tremendous opportunities.
  • In the first quarter of 2026, we generated net product sales of just under 55 million, representing a 26% growth compared to the first quarter of 2025.
  • we expect to return to sequential growth starting in the second quarter driven by improving demand trends.

Bear points

  • The increase in costs and expenses was primarily due to increased research and development costs, driven by the timing of clinical activities related to R289, as well as increased commercial-related expenses and personnel-related costs.
  • We reported net income of $8.7 million for the first quarter, compared to net income of $11.4 million in the same period in 2025.
  • Gavretto Revenue seems to be plateauing in 1Q.
Read full transcript analysis ›